Ok, now back to the Polycap. You can watch an ABC News story here to get more info, but I want to discuss what is next.
They are suggesting a large follow up study. This is a perfect time for Canada's Health bodies to get behind this world leader in his field and make the follow-up study happen. It is most likely not a study that the BIG PHARMA group is going to fund. These are drugs that have gone off Patent. The Generic Industry most likely will not do this either. One of the cornerstones of this product is that it can save $ and lives. If, it saves dollars, then someone is not making as much. That is a simple fact. So who could see lost revenue from the introduction of such a pill. I suspect the list includes the following, Big Pharma, Pharmacy (one prescription as opposed to 5), Insurance (if they are based on % of book of business), wholesalers, Generic companies (lost revenue of selling 5 products), and perhaps even Consultants dependent on how their payments are structured. So really it encompasses the whole supply chain. But look at the masses that could potentially benefit. Imagine, Benefit plans and government plans could save money thereby allowing more new break through drugs on their formularies. The potential benefits may well be there in the end for the supply chain.
The US Health structure promotes a desire to reduce pharmaceutical expenditures . If a study is going to happen in the US , I hope we are getting behind Dr. Yusuf and helping him make this happen here in Canada.
Something for future consideration is the following.... If the Study is done and indeed it proves that it saves lives, reduces expenditures, improves compliance,and makes it to market, how will it be promoted? Or Who will Promote it? As from the Ramipril vs Lisinopril explanation, marketing is very very necessary.